Curevac Nv Stock Performance
| CVAC Stock | USD 3.96 0.18 4.35% |
On a scale of 0 to 100, CureVac NV holds a performance score of 11. The firm shows a Beta (market volatility) of 1.18, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CureVac NV will likely underperform. Please check CureVac NV's total risk alpha, value at risk, expected short fall, as well as the relationship between the treynor ratio and downside variance , to make a quick decision on whether CureVac NV's price patterns will revert.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in CureVac NV are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, CureVac NV exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.35) | Five Day Return (5.49) | Year To Date Return 14.78 | Ten Year Return (92.92) | All Time Return (92.92) |
1 | CureVac to Present at the 12th International mRNA Health Conference | 11/04/2024 |
2 | CureVac N.V. Q3 2024 Earnings Call Transcript | 11/13/2024 |
3 | CureVac Shares Gap Down Time to Sell | 11/15/2024 |
4 | CureVac NV Float Percentage Of Total Shares Outs - GuruFocus.com | 11/21/2024 |
5 | CureVacs SWOT analysis mRNA pioneers stock faces pivotal phase in oncology push | 12/04/2024 |
6 | CUREVAC Licensing deal boosts bank account - Marketscreener.com | 12/12/2024 |
7 | ASPIRE Level 1 Outcomes Published Demonstrating Superior Stone Clearance with the SURE Procedure using the CVAC System vs. Standard Ureteroscopy | 12/23/2024 |
8 | US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses Vaccine Stocks Rally | 01/07/2025 |
9 | CureVac Shares Gap Down Heres What Happened | 01/10/2025 |
10 | Bird Flu Update First Commercial Case In Georgia, Moderna Receives 590 Million To Develop Vaccine | 01/21/2025 |
| Begin Period Cash Flow | 495.8 M |
CureVac |
CureVac NV Relative Risk vs. Return Landscape
If you would invest 275.00 in CureVac NV on October 25, 2024 and sell it today you would earn a total of 121.00 from holding CureVac NV or generate 44.0% return on investment over 90 days. CureVac NV is currently generating 0.7203% in daily expected returns and assumes 4.8584% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than CureVac, and 86% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CureVac NV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CureVac NV's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CureVac NV, and traders can use it to determine the average amount a CureVac NV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1482
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CVAC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.86 actual daily | 43 57% of assets are more volatile |
Expected Return
| 0.72 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average CureVac NV is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CureVac NV by adding it to a well-diversified portfolio.
CureVac NV Fundamentals Growth
CureVac Stock prices reflect investors' perceptions of the future prospects and financial health of CureVac NV, and CureVac NV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CureVac Stock performance.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (4.94) % | ||||
| Current Valuation | 352.71 M | ||||
| Shares Outstanding | 224.34 M | ||||
| Price To Book | 1.18 X | ||||
| Price To Sales | 13.49 X | ||||
| Revenue | 53.76 M | ||||
| Gross Profit | (86.28 M) | ||||
| EBITDA | (234.09 M) | ||||
| Net Income | (260.17 M) | ||||
| Cash And Equivalents | 540.87 M | ||||
| Cash Per Share | 2.85 X | ||||
| Total Debt | 41.82 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.61 X | ||||
| Book Value Per Share | 1.68 X | ||||
| Cash Flow From Operations | (267.89 M) | ||||
| Earnings Per Share | 0.49 X | ||||
| Market Capitalization | 888.38 M | ||||
| Total Asset | 788.25 M | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 291.99 M | ||||
About CureVac NV Performance
By analyzing CureVac NV's fundamental ratios, stakeholders can gain valuable insights into CureVac NV's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CureVac NV has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CureVac NV has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 83.71 | 132.40 | |
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.58) | (0.61) |
Things to note about CureVac NV performance evaluation
Checking the ongoing alerts about CureVac NV for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CureVac NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CureVac NV appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 53.76 M. Net Loss for the year was (260.17 M) with loss before overhead, payroll, taxes, and interest of (86.28 M). | |
| CureVac NV currently holds about 540.87 M in cash with (267.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.85. | |
| Roughly 45.0% of the company shares are held by company insiders | |
| Latest headline from benzinga.com: Bird Flu Update First Commercial Case In Georgia, Moderna Receives 590 Million To Develop Vaccine |
- Analyzing CureVac NV's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CureVac NV's stock is overvalued or undervalued compared to its peers.
- Examining CureVac NV's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CureVac NV's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CureVac NV's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CureVac NV's stock. These opinions can provide insight into CureVac NV's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |